Skip to main content
Top
Published in: BMC Gastroenterology 1/2019

Open Access 01-12-2019 | Wilson's Disease | Case report

Drug induced hepatitis mimicking Wilson’s disease secondary to the use of complex naturopathic regimens: a case report

Authors: Tyler Pitre, Jasmine Mah, Jaclyn Vertes, Rosario Rebello, Julie Zhu

Published in: BMC Gastroenterology | Issue 1/2019

Login to get access

Abstract

Background

Drug induced liver injury (DILI) is an important cause of acute liver injury and accounts for approximately 10% of all cases of acute hepatitis. Both prescription and natural health products (NHPs) have been implicated in DILI. There is a dearth of studies on NHPs induced liver injury.

Case Presentation

A previously healthy 37-year-old female presented with subacute hepatitis, in the context of a previous admission to a separate institution, months prior for undiagnosed acute hepatitis. Importantly, she had disclosed taking complex regiments of natural health products (NHPs) for months. Her only other medication was rivaroxaban for her homozygous Factor V Leiden deficiency. She had an extensive work up for causes of acute and unresolving hepatitis. She discontinued several but not all of her NHPs after her initial presentation for acute hepatitis at the first institution and continued taking NHPs until shortly after admission to our institution. The predominant pathological features were that of drug induced liver injury, although an abnormal amount of copper was noted in the core liver biopsies. However, Wilson’s disease was ruled out with normal serum ceruloplasmin and 24-urine copper. After 2 months of stopping all the NHPs, our patient improved significantly since discharge, although there is evidence of fibrosis on ultrasound at last available follow up.

Conclusion

NHPs are a well-established but poorly understood etiology of DILI. The situation is exacerbated by the unregulated and unpredictable nature of many of the potential hepatotoxic effects of these agents, especially in cases of multiple potential toxic agents. This highlights the importance of acquiring a clear history of all medications regardless of prescription status.
Footnotes
1
With AST = 56, ALT = 61, Platelets = 116,000, age = 37.
 
Literature
9.
go back to reference LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institutes of Health, Rockville, Updated 01 November 2018. Available from: https://livertox.nih.gov. Cited 2019 Jun 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institutes of Health, Rockville, Updated 01 November 2018. Available from: https://​livertox.​nih.​gov. Cited 2019 Jun 15.
10.
go back to reference Lambert A, Cordeanu M, Gaertner S, Nouri S, Alt M, Stephan D. Rivaroxaban-induced liver injury: Results from a venous thromboembolism registry. Int J Cardiol. 2015;191:265–6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25981364. [cited 2019 Jun 15].CrossRef Lambert A, Cordeanu M, Gaertner S, Nouri S, Alt M, Stephan D. Rivaroxaban-induced liver injury: Results from a venous thromboembolism registry. Int J Cardiol. 2015;191:265–6 Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25981364.​ [cited 2019 Jun 15].CrossRef
Metadata
Title
Drug induced hepatitis mimicking Wilson’s disease secondary to the use of complex naturopathic regimens: a case report
Authors
Tyler Pitre
Jasmine Mah
Jaclyn Vertes
Rosario Rebello
Julie Zhu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2019
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-019-1122-x

Other articles of this Issue 1/2019

BMC Gastroenterology 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.